Linked Life Data

1868632

Source:http://linkedlifedata.com/resource/pubmed/id/1868632

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1991-9-19
pubmed:abstractText
The 1990s may revolutionize the care of the fetus and create new options in gene control, immunotherapy, and drug therapy not only to identify susceptible populations but to treat selectively that population without increasing the risk to the mother. Fetal therapy is a notable goal, even now somewhat within our grasp. No longer is the womb an isolated, forbidding environment, but it is accessible with such tools as magnetic resonance imaging, ultrasonography, CVS, Doppler, and sound clinical judgement. Current limitations in our understanding of the pharmacokinetics associated with these chemical temper our enthusiasm. The development of biomarkers for appropriate fetal drug therapy is to be encouraged, but also the development of fetal and maternal biomarkers that will assist the physician in actively avoiding inappropriate fetal drug therapy is necessary, whether dose or chemical dependent.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0009-9201
pubmed:author
pubmed:issnType
Print
pubmed:volume
34
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
241-50
pubmed:dateRevised
2009-11-11
pubmed:meshHeading
pubmed:year
1991
pubmed:articleTitle
Fetal drug therapy: principles and issues.
pubmed:affiliation
University of Rochester Medical Center, New York.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Review